Know Cancer

forgot password

HIV Indicator Diseases Across Europe Study

18 Years
64 Years
Open (Enrolling)

Thank you

Trial Information

HIV Indicator Diseases Across Europe Study

Most patients infected with HIV across the European continent remain undiagnosed; although
this percentage varies markedly from 15-80% across the continent. Undiagnosed HIV is harmful
to the person infected as appropriate health interventions are then delayed until the HIV
infection is diagnosed. It is also detrimental to society as persons unaware of their HIV
infection may transmit more frequently to others than persons that are aware of their HIV

An important public health issue is hence how to diagnose more HIV-infected persons earlier
in the course of their infection. In the US, the Centers for Disease Control and Prevention
(CDC) has introduced testing guidelines where all persons are tested upon entry into the
hospital system (the "opt-out" testing guidelines).

At the "HIV in Europe" conference held in November 2007, the general sense was that such an
approach would not be suitable for Europe. Conversely, the conference recommended further
development of focused HIV testing in patients presenting with certain clinical conditions
and/or diseases (i.e. indicator condition guided testing).

Cost effectiveness analyses suggests cost savings if a population with a HIV prevalence of
1% or more are tested although this rate may be as low as 0.1%. However, there is very
little - if any - evidence on HIV prevalence for various conditions and diseases in specific
and easy to identify sections of society. This is true in general and particularly across
the European continent.

Surveys will be undertaken by the investigators:

Zangerle, Kitchen, U H Innsbruck, Vassilenko, Minsk Municipal Infectious Diseases Hospital,
Necsoi, Clumeck, Saint-Pierre U H Hadziosmanovic, U of Sarajevo Begovac, U Hospital of
Infectious Diseases Pedersen, Mogensen, Abildgaard, Titlestad, Odense U H Dragsted, Roskilde
H Sp├Ąth, U of Bonn Sthoeger, Neve-Or AIDS Centre d'Armino Monforte, Mareo, Comi, Centanni,
San Paolo H Grzeszczuk, Medical U of Bialystok Maltez, H Curry Cabral Castro, HU A
Coruna-Hospital Juan Canalejo Masia, HU Elche Estrada, HCU San Carlos Iribarren, H. Donostia
Ortega, CH General de Valencia Ocampo, H Xeral-Cies Vernazza, Kantonsspital St. Gallen
Perry, Fisher, Elton John Centre, Morris, RIDU Minton, St James's U H Palfreeman, Leicester
Royal Infirmary Gazzard, Sullivan, ChelseaWestminster H Winston, Walsh, St Mary's H
Anderson, Millett, Homerton H NHS Trust Farazmand, Huddersfield Royal Infirmary Ong,
Krasnov, Kharkov Regional Clinic of Infectious Diseases Kutsyna, State Medical U

Inclusion Criteria:

- HIV status unknown

- Presenting for care with 1 of the 11 indicator diseases surveyed.

Exclusion Criteria:

- Known HIV positive

Type of Study:


Study Design:

Time Perspective: Prospective

Outcome Measure:

Prevalence of HIV

Outcome Description:

To assess the HIV prevalence for the identified diseases and/or conditions within a specific segment of the population not yet diagnosed with HIV and that present for care with the specific disease/condition.

Outcome Time Frame:

Participants are surveyed once up to month 23 for presenting indicator disease and result of the HIV test performed. Per site 100 participants are included in each survey - in total the single survey requires minimum 400 participants from all sites

Safety Issue:


Principal Investigator

Jens D Lundgren, Prof.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Copenhagen


Denmark: Ethics Committee

Study ID:




Start Date:

February 2012

Completion Date:

June 2014

Related Keywords:

  • HIV
  • HIV
  • Indicator disease